AI Driven Drug Firm Partners With Merck

Source: Streetwise Reports   01/07/2022

Shares of Absci Corp. rose 18% after the company reported it is collaborating with Merck & Co. to create enzymes using its deep-learning Integrated Drug Creation™ platform and Bionic Protein™ technologies.

This morning before U.S. markets opened for trading, drug and target discovery company Absci Corp. (ABSI:NASDAQ), which utilizes deep learning artificial intelligence (AI) and synthetic biology to harness and expand the therapeutic potential of proteins, announced that “it has entered into a research collaboration with Merck & Co. Inc. (MRK:NYSE) (known as MSD outside the U.S. and Canada), using Absci’s AI-powered Integrated Drug Creation™ Platform.”

The agreement between the two firms provides that Absci will produce enzymes tailored to Merck’s specific biomanufacturing applications using its Bionic Protein™ non-standard amino acid technology.

In return, Merck will pay the company unspecified upfront fees and other various milestone payments.

In addition, Merck will have the option rights to select up to three targets of its choosing and enter into a drug discovery collaboration agreement. Under that scenario, the report indicated that Absci would then be eligible to receive as much as $610 million in upfront fees and milestone achievement payments for each of the three targets, along with further research funding and tiered royalties on any future sales.

Absci Corp.’s founder and CEO Sean McClain stated, “We are very pleased to establish this collaboration with Merck and to be working with its world class research organization to generate novel enzymes. We look forward to applying our AI-driven platform to create new biologic candidates with the potential to meaningfully improve the lives of patients.”

Merck Research Laboratories’ SVP and head of discovery, preclinical and translation medicine Dr. Fiona Marshall remarked, “At Merck we are continually evaluating new ways to build, expand and refine our biologics capabilities…Absci’s platform offers a compelling opportunity to design new biologic candidates and explore the expression of complex proteins.”

Absci is a drug and target discovery company headquartered in Vancouver, Wash that combines the use of deep learning AI with synthetic biology to expand proteins therapeutic potential. The company explained that it “built its Integrated Drug Creation™ Platform to identify novel drug targets, discover optimal biotherapeutic candidates and generate the cell lines to manufacture them in a single efficient process.” Absci partners with biotech and pharmaceutical companies to create and develop next generation of protein-based medicines.

Merck is one of the world’s largest global healthcare companies based in Kenilworth, N.J. The company has a market cap of about $200 billion and is known as MSD outside of the U.S. and Canada. The firm is a global provider of healthcare services and developer, manufacturer and marketer of animal health products, biologic therapies, prescription medicines and vaccines. The company strives to be the world’s premier research-intensive biopharmaceutical company.

Absci Corp. began the day with a market cap of around $568.5 million with approximately 92.6 million shares outstanding and a short interest of about 3.1%. ABSI shares opened greater than 48% higher today at $9.11 (+$2.97, +48.37%) over yesterday’s $6.12 closing price. The stock has traded today between $7.53 and $9.26 per share and is currently trading at $7.26 (+$1.12, +18.24%).

Disclosure:
1) Stephen Hytha compiled this article for Streetwise Reports LLC and provides services to Streetwise Reports as an independent contractor. He or members of his household own securities of the following companies mentioned in the article: None. He or members of his household are paid by the following companies mentioned in this article: None.
2) The following companies mentioned in this article are billboard sponsors of Streetwise Reports: None. Click here for important disclosures about sponsor fees.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
4) The article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports’ terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the decision to publish an article until three business days after the publication of the article. The foregoing prohibition does not apply to articles that in substance only restate previously published company releases.
6) This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.